A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung Cancer Patients-Reference-Cited by-同舟云学术

A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non–Small-Cell Lung Cancer Patients

Published:2017-09 Issue:5 Volume:18 Page:572-582.e1
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Takada Kazuki,Toyokawa Gouji,Okamoto Tatsuro,Shimokawa Mototsugu,Kozuma Yuka,Matsubara Taichi,Haratake Naoki,Akamine Takaki,Takamori Shinkichi,Katsura Masakazu,Shoji Fumihiro,Oda Yoshinao,Maehara Yoshihiko

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Cancer statistics, 2012;Siegel;CA Cancer J Clin,2012

2. Molecularly targeted therapies in non–small-cell lung cancer annual update 2014;Morgensztern;J Thorac Oncol,2015

3. New targetable oncogenes in non–small-cell lung cancer;Oxnard;J Clin Oncol,2013

4. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

5. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Revisiting the impact of clinicopathologic characteristics in PD-L1 profile in a large cohort of non-small cell lung cancer;Translational Lung Cancer Research;2024-03

2. Predictions of PD-L1 Expression Based on CT Imaging Features in Lung Squamous Cell Carcinoma;Journal of the Korean Society of Radiology;2024

3. Immunotherapy Efficacy Prediction for Non-Small Cell Lung Cancer Using Multi-View Adaptive Weighted Graph Convolutional Networks;IEEE Journal of Biomedical and Health Informatics;2023-11

4. Role of lymphocytes, macrophages and immune receptors in suppression of tumor immunity;Progress in Molecular Biology and Translational Science;2023

5. In silico mapping of the dynamic interactions and structure-activity relationship of flavonoid compounds against the immune checkpoint programmed-cell death 1 pathway;Frontiers in Drug Discovery;2022-12-12